19 completed, 14 recruiting, 3 active not recruiting, 3 not yet recruiting. 26 Phase 1, 22 Phase 2, 4 Phase 3.
Follow Dizal Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) DZD8586, Rabeprazole - Healthy | Phase 1 | Recruiting | Dizal Pharmaceuticals | 26 | 2026-10-23 | 2026-11-06 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) GW5282 combined with Golidocitinib, Conventional CHOP regimen - T-cell Lymphomas | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2026-04-15 | 2026-10-22 |
| A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) DZD8586 - Lymphoma, Non-Hodgkin | Phase 1 | Completed | Dizal Pharmaceuticals | 6 | 2026-03-16 | 2026-05-14 |
| A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors GW5282 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 203 | 2026-01-29 | 2026-02-11 |
| A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2026-01-15 | 2026-01-22 |
| A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) DZD8586, Venetoclax - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Dizal Pharmaceuticals | 66 | 2025-09-22 | 2026-06-22 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 250 | 2025-09-08 | 2026-06-03 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 150 | 2025-08-19 | 2026-04-01 |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) DZD6008, Sunvozertinib, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2025-07-30 | 2026-10-23 |
| DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) DZD6008, Pemetrexed, Carboplatin - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 180 | 2025-07-16 | 2026-08-31 |
| A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) DZD6008, Sunvozertinib - Non Small Cell Lung Cancer | Phase 1 | Recruiting | Dizal Pharmaceuticals | 140 | 2025-05-13 | 2026-10-23 |
| Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) DZD6008 - Nonsmall-cell Lung Cancer | Phase 1 | Recruiting | Dizal Pharmaceuticals | 300 | 2024-06-12 | 2026-08-28 |
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Golidocitinib, Chidamide, Gemcitabine - Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 218 | 2024-05-13 | 2026-06-08 |
| DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) DZD8586 - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Dizal Pharmaceuticals | 155 | 2024-04-29 | 2026-06-02 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) DZD8586 - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 59 | 2024-03-13 | 2026-08-04 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) Golidocitinib, Sintilimab, platinum doublet chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2024-01-01 | 2024-01-10 |
| DZD9008 PK Study in Hepatic Impairment Subjects DZD9008 - Hepatic Impairment | Phase 1 | Completed | Dizal Pharmaceuticals | 17 | 2023-10-17 | 2024-12-18 |
| Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin) - Non-small Cell Lung Cancer | Phase 1 | Completed | Dizal Pharmaceuticals | 25 | 2023-07-31 | 2024-12-13 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Lymphoma, T-Cell, Peripheral (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Large Granular Lymphocytic (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Recurrence (1) · Sezary Syndrome (1)
Carbamazepine (2) · Rituximab (2) · Ado-Trastuzumab Emtansine (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Digoxin (1) · Docetaxel (1) · Doxorubicin (1) · Gemcitabine (1) · Itraconazole (1) · Midazolam (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Pemetrexed (1)
China (28) · United States (16) · Australia (6) · South Korea (3) · Argentina (2) · Canada (2) · France (2) · Italy (2) · Spain (2) · Taiwan (2) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1)
Jianyong Li (2) · Mengzhao Wang (2) · Tianwei Zhang (2) · Anne Zhang (1) · Caicun Zhou (1) · Daniel Dickerson (1) · Eric Lawitz, MD (1) · Frank Lee, MD (1) · Gregory J Tracey (1) · Jie Jin (1)
PMID 38101437, PMID 36229853, PMID 37077916, PMID 37415239, PMID 38092009, PMID 38924456, PMID 40782807, PMID 40923280, PMID 42212913